Cargando…
DDRE-08. NRF2/GLUTATHIONE METABOLISM AS A NOVEL THERAPEUTIC TARGET FOR IDH1-MUTATED GLIOMA
BACKGROUND: IDH1-mutated glioma is a recently defined disease entity with distinctive patterns of tumor cell biology, metabolism, and resistance to therapy. Although IDH1 mutations are highly prevalent in patients with WHO II/III glioma, curative molecular targeting approaches remain unavailable for...
Autores principales: | Liu, Yang, Yu, Di, Celiku, Orieta, Li, Aiguo, Larion, Mioara, Yang, Chunzhang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992271/ http://dx.doi.org/10.1093/noajnl/vdab024.030 |
Ejemplares similares
-
DDRE-20. TARGETING SPHINGOLIPID PATHWAY REVEALS VULNERABILITY IN IDH1(MUT) GLIOMA
por: Dowdy, Tyrone, et al.
Publicado: (2021) -
DDRE-27. IDH MUTATED GLIOMAS PROMOTE EPILEPTOGENESIS VIA D-2-HYDROXYGLUTARATE DEPENDENT MTOR HYPERACTIVATION
por: Mortazavi, Armin, et al.
Publicado: (2021) -
DDRE-01. METABOLIC PLASTICITY AND HETEROGENEITY IN IDH1MUT CELL LINES PRODUCES RESISTANCE TO GLUTAMINASE INHIBITION BY CB839
por: Larion, Mioara, et al.
Publicado: (2021) -
DDRE-16. CYSTEINE IS AN ESSENTIAL AMINO ACID IN GLIOMAS
por: Ruiz-Rodado, Victor, et al.
Publicado: (2021) -
DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)